South San Francisco, CA, United States of America

Pionyr Immunotherapeutics, Inc.


USPTO Granted Patents = 6

Trademarks = 1

Forward Citations = 0

Loading Chart...
Loading Chart...

17 inventors (with patents filed for the assignee):

goldMedal Leonard G Presta (6 out of 215 patents)

silverMedal Venkataraman Sriram (5 out of 7 patents)

bronzeMedal Aritra Pal (5 out of 5 patents)

4.  Michel Streuli (4 out of 13 patents)

5.  Linda Liang (3 out of 22 patents)

6.  Christopher Chan (2 out of 17 patents)

7.  Tiep Tu Le (2 out of 2 patents)

8.  Nadine Jahchan (2 out of 3 patents)

9.  Joshua Pollack (2 out of 3 patents)

10.  Sayantan Mitra (1 out of 8 patents)

11.  Mikhail Binnewies (1 out of 2 patents)

12.  Xi Yang (1 out of 2 patents)

13.  Kara Mojica (1 out of 2 patents)

14.  Vladislava Juric (1 out of 2 patents)

15.  Linnea Haeggblom (1 out of 2 patents)


6 patents:

Company Overview
Pionyr Immunotherapeutics, Inc. is a biotechnology company focused on developing novel immunotherapies for cancer. Their proprietary platform targets the tumor microenvironment to enhance the body’s immune response against cancer cells. Pionyr’s innovative approach holds promise for improving patient outcomes and advancing the field of immuno-oncology.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

6 Patents

#137 in South San Francisco, CA

#10,578 in California

#45,007 in US

South San Francisco, CA (US)
South San Francisco, CA, United States of America
Forward Citations = 0

17 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Pionyr Immunotherapeutics, Inc.. Retrieved from https://idiyas.com/company/pionyr-immunotherapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…